{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:58:34Z","timestamp":1785365914556,"version":"3.55.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary non-response to anti-tumor necrosis factor (anti-TNF) therapy remains a major clinical challenge in ulcerative colitis (UC); however, public-data transcriptomic studies often yield unstable single-gene biomarkers and limited replication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed three independent pretreatment UC mucosal transcriptome cohorts from infliximab-treated patients (total n = 79). The induction response was assessed at 4\u20138\u00a0weeks according to the original definition in each study. To prioritize cross-cohort biology over single-probe overlap, we integrated recurrent effect direction, pathway convergence, and sample-level scoring. We defined a 68-gene consensus signature for interpretation, evaluated generalization with leave-one-dataset-out (LODO) scoring, tested attenuation after adjusting for baseline inflammatory\/remodeling proxies, and examined cellular localizations in public epithelial (GSE116222) and rectal immune (GSE125527) single-cell references.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 68-gene consensus signature was higher in non-responders across all three cohorts. In the LODO analysis, the held-out non-response axis remained elevated in the held-out non-responders, with a pooled random-effects size of Hedges\u2019 g = 1.36 (95% confidence interval: 0.83\u20101.89;\n                      <jats:italic>p<\/jats:italic>\n                      = 5.65 \u00d7 10\n                      <jats:sup>\u22127<\/jats:sup>\n                      ; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). The pathway analyses consistently implicated inflammatory responses, TNF-\u03b1\/NF-\u03baB, IL-6\u2013JAK\u2013STAT3, interferon signaling, hypoxia, and epithelial\u2013mesenchymal transition (EMT), whereas oxidative phosphorylation was enriched in the responders. Adjustments for inflammatory proxies with and without EMT attenuated the effects, but the associations remained directionally positive in all cohorts and retained nominal significance in two cohorts under the strictest model. In public single-cell references, the signature activities were enriched in cycling\/stem-like and stress-inflammatory epithelial states and were highest in the rectal myeloid\/dendritic cells (M\/DCs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the infliximab-treated UC cohorts, induction-phase non-response is associated with reproducible pretreatment mucosal-inflammatory-remodeling states that remain evident in the held-out cross-cohort analyses while localizing most strongly to rectal M\/DCs and stress-associated epithelial states in public single-cell references. The signal overlaps substantially with the baseline inflammatory\/remodeling burden, but its direction is consistent across the cohorts. These findings support a biologically coherent disease-state framework rather than a deployable clinical predictor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1845510","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:10:13Z","timestamp":1785363013000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A reproducible pretreatment mucosal-inflammatory-remodeling state is associated with induction-phase anti-tumor necrosis factor non-response in ulcerative colitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongwei","family":"Zheng","sequence":"first","affiliation":[{"name":"Quanzhou Medical College","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Quanzhou First Hospital Affiliated to Fujian Medical University","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Quanzhou Medical College","place":["Quanzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14712598.2023.2198086","article-title":"Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?","volume":"23","author":"Anjie","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1172\/JCI121668","article-title":"IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease","volume":"129","author":"Belarif","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"eabb4432","DOI":"10.1126\/sciimmunol.abb4432","article-title":"Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses","volume":"5","author":"Boland","year":"2020","journal-title":"Sci. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2665-9913(23)00341-7","article-title":"Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials","volume":"6","author":"Brun","year":"2024","journal-title":"Lancet Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ueg2.12720","article-title":"Multi-omics biomarkers for predicting efficacy of biologic and small-molecule therapies in adults with inflammatory bowel disease: a systematic review","volume":"13","author":"Chen","year":"2025","journal-title":"United Eur. Gastroenterol. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103329","DOI":"10.1016\/j.ebiom.2021.103329","article-title":"Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: current and novel biomarkers","volume":"66","author":"Cui","year":"2021","journal-title":"EBioMedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"881112","DOI":"10.3389\/fimmu.2022.881112","article-title":"Could mucosal TNF transcript as a biomarker candidate help optimize Anti-TNF biological therapy in patients with ulcerative colitis?","volume":"13","author":"Cui","year":"2022","journal-title":"Front. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"17589","DOI":"10.2147\/JIR.S546252","article-title":"Identifying genetic factors influencing the development of anti-drug antibodies in inflammatory bowel disease: a scoping review","volume":"18","author":"Culmsee-Holm","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/ibd\/izae046","article-title":"Hypoxic functional regulation pathways in the GI tract: focus on the HIF-1\u03b1 and microbiota\u2019s crosstalk","volume":"30","author":"Di Mattia","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/apt.17622","article-title":"Review article: translating STRIDE-II into clinical reality - opportunities and challenges","volume":"58","author":"Dignass","year":"2023","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/ecco-jcc\/jjz195","article-title":"Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"14","author":"Gisbert","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/gutjnl-2024-334165","article-title":"Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications","volume":"74","author":"Gudi\u00f1o","year":"2025","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00424-024-02943-y","article-title":"Role of pH-sensing receptors in colitis","volume":"476","author":"Hausmann","year":"2024","journal-title":"Pflugers Arch."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"jjaf233","DOI":"10.1093\/ecco-jcc\/jjaf233","article-title":"Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use","volume":"20","author":"Hodges","year":"2026","journal-title":"J. Crohns Colitis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"goae030","DOI":"10.1093\/gastro\/goae030","article-title":"Hypoxia, hypoxia-inducible factors and inflammatory bowel diseases","volume":"12","author":"Hou","year":"2024","journal-title":"Gastroenterol. Rep. (Oxf)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e168988","DOI":"10.1172\/jci.insight.168988","article-title":"Gene coexpression networks reveal a broad role for lncRNAs in inflammatory bowel disease","volume":"9","author":"Johnson","year":"2024","journal-title":"JCI Insight"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/060012","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2016","journal-title":"bioRxiv"},{"key":"B22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.medj.2022.05.002","article-title":"Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases","volume":"3","author":"Korsunsky","year":"2022","journal-title":"Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J. Clin. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"B25","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41575-024-00989-y","article-title":"Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease","volume":"21","author":"Ma","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1490533","DOI":"10.3389\/fmolb.2024.1490533","article-title":"Individual-network based predictions of microbial interaction signatures for response to biological therapies in IBD patients","volume":"11","author":"Melograna","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"jjaf076","DOI":"10.1093\/ecco-jcc\/jjaf076","article-title":"Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients","volume":"19","author":"Mel\u00f3n-Ardanaz","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British society of gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1530508","DOI":"10.3389\/fimmu.2025.1530508","article-title":"Developing models for the diagnosing of ulcerative colitis and prognosis of anti-TNF-\u03b1 non-response based on neutrophil extracellular trap-associated genes","volume":"16","author":"Ou","year":"2025","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41586-019-0992-y","article-title":"Colonic epithelial cell diversity in health and inflammatory bowel disease","volume":"567","author":"Parikh","year":"2019","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2266626","DOI":"10.1080\/19490976.2023.2266626","article-title":"Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis","volume":"15","author":"Pe\u00f1a-Cearra","year":"2023","journal-title":"Gut Microbes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"112943","DOI":"10.1016\/j.intimp.2024.112943","article-title":"Focusing on non-responders to infliximab with ulcerative colitis, what can we do first and next?","volume":"141","author":"Pu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.jmoldx.2024.06.008","article-title":"A network-based framework to discover treatment-response-predicting biomarkers for complex diseases","volume":"26","author":"Shanthamallu","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"B38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2018.06.077","article-title":"Gene expression signature for prediction of golimumab response in a phase 2a open-label trial of patients with ulcerative colitis","volume":"155","author":"Telesco","year":"2018","journal-title":"Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/s41590-024-01994-8","article-title":"A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease","volume":"25","author":"Thomas","year":"2024","journal-title":"Nat. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/ajg.2011.83","article-title":"Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis","volume":"106","author":"Toedter","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2105-7-91","article-title":"Bias in error estimation when using cross-validation for model selection","volume":"7","author":"Varma","year":"2006","journal-title":"BMC Bioinformatics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"jjaf162","DOI":"10.1093\/ecco-jcc\/jjaf162","article-title":"Blood proteomic signatures associated with disease activity in inflammatory bowel diseases","volume":"19","author":"Veyssi\u00e8re","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1611598","DOI":"10.3389\/fimmu.2025.1611598","article-title":"Multi-omics derivation of a core gene signature for predicting therapeutic response and characterizing immune dysregulation in inflammatory bowel disease","volume":"16","author":"Wang","year":"","journal-title":"Front. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"jjae152","DOI":"10.1093\/ecco-jcc\/jjae152","article-title":"Crohn\u2019s disease and ulcerative colitis share 2 molecular subtypes with different mechanisms and drug responses","volume":"19","author":"Wang","year":"","journal-title":"J. Crohns Colitis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm12196292","article-title":"Benefits and challenges of treat-to-target in inflammatory bowel disease","volume":"12","author":"West","year":"2023","journal-title":"J. Clin. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/ibd\/izad060","article-title":"Novel mRNA signature for anti-TNF-\u03b1 therapy primary response in patients with ulcerative colitis","volume":"29","author":"Yang","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41401-025-01695-4","article-title":"Formyl peptide receptor 2 is a potential biomarker and therapeutic target for inflammatory bowel disease","volume":"47","author":"Yang","year":"2026","journal-title":"Acta Pharmacol. Sin."},{"key":"B53","doi-asserted-by":"publisher","first-page":"jjaf195","DOI":"10.1093\/ecco-jcc\/jjaf195","article-title":"HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease","volume":"19","author":"Zhang","year":"2025","journal-title":"J. Crohns Colitis"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1845510\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:10:15Z","timestamp":1785363015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1845510\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":53,"alternative-id":["10.3389\/fgene.2026.1845510"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1845510","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"article-number":"1845510"}}